search

Active clinical trials for "Immune System Diseases"

Results 111-120 of 37852

Standard Doses of Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed...

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

This phase I/II trial studies the safety of the combination of bortezomib, dexamethasone, and pembrolizumab with or without pelareorep in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refractory). Chemotherapy drugs, such as bortezomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. A virus modified in the laboratory, such as pelareorep, may be able to kill cancer cells without damaging normal cells. Giving the combination of bortezomib, dexamethasone, and pembrolizumab with pelareorep may work better in treating patient with multiple myeloma.

Recruiting67 enrollment criteria

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Adult Participants With Moderate to Severe...

Dermatitis Atopic

This is a single group, Phase 2, long-term extension study for treatment. The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated adult participants with moderate to severe AD who have previously been enrolled in study KY1005-CT05 (DRI17366). Visits during the on-treatment period will be at Week 0, 1, 2, 4 and every 4 weeks (Q4W) thereafter. If remote or telephone visits are considered appropriate for participants instead of clinic visits at the timepoints indicated in the schedule of activities (SoA), home visits (e.g., home nurses, etc) will be required for administration of investigational medicinal product (IMP) and assessment of vital signs. This decision is at the discretion of the investigator.

Recruiting20 enrollment criteria

A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin...

Advanced Solid TumorMetastatic Solid Tumor1 more

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

Recruiting12 enrollment criteria

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent...

Urticaria

Determine the effect of ARS-1 on a patient reported pruritus/hive score

Recruiting18 enrollment criteria

Remote Care in People With Rheumatoid Arthritis

Rheumatoid Arthritis

This study is a 24-months, non-inferiority randomized, controlled trial with two parallel arms to determine if a new follow-up strategy for patients with RA is non-inferior in maintaining comprehensive disease control measured as simultaneous maintenance of structural, functional and clinical treatment target at 2-year follow-up compared to the conventional follow-up regimen with regular hospital visits.

Recruiting21 enrollment criteria

A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib...

Relapsed or Refractory Multiple Myeloma

The purpose of this study is to compare the efficacy and safety of CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Recruiting10 enrollment criteria

This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With...

Relapsed and/or Refractory Multiple Myeloma

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0591CP in patients with relapsed and/or refractory multiple myeloma.

Recruiting33 enrollment criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma)...

Mantle Cell LymphomaNon Hodgkin Lymphoma1 more

To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

Recruiting79 enrollment criteria

The Effect of Backward Walking Training on Balance, Gait and Functional Mobility in Patients With...

Multiple Sclerosis

Backward walking training can be a useful treatment approach, providing novel balance and gait challenges. It can lead to improve balance, gait and functional mobility in neurologic populations. However, the effect of backward walking training has net been investigated in people with multiple sclerosis.

Recruiting9 enrollment criteria

Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children

Newly Diagnosed Immune Thrombocytopenia in ChildrenFirst Line Treatment

To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate

Recruiting11 enrollment criteria
1...111213...3786

Need Help? Contact our team!


We'll reach out to this number within 24 hrs